KR102389552B1 - Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 - Google Patents

Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 Download PDF

Info

Publication number
KR102389552B1
KR102389552B1 KR1020167031180A KR20167031180A KR102389552B1 KR 102389552 B1 KR102389552 B1 KR 102389552B1 KR 1020167031180 A KR1020167031180 A KR 1020167031180A KR 20167031180 A KR20167031180 A KR 20167031180A KR 102389552 B1 KR102389552 B1 KR 102389552B1
Authority
KR
South Korea
Prior art keywords
compound
mdm2
cancer
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167031180A
Other languages
English (en)
Korean (ko)
Other versions
KR20160136450A (ko
Inventor
샤오멩 왕
안젤로 아길라
리우 리우
지안펭 루
도나 매키천
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시간
Priority to KR1020227012871A priority Critical patent/KR102599945B1/ko
Publication of KR20160136450A publication Critical patent/KR20160136450A/ko
Application granted granted Critical
Publication of KR102389552B1 publication Critical patent/KR102389552B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020167031180A 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 Active KR102389552B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227012871A KR102599945B1 (ko) 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980747P 2014-04-17 2014-04-17
US61/980,747 2014-04-17
PCT/US2015/026098 WO2015161032A1 (en) 2014-04-17 2015-04-16 Mdm2 inhibitors and therapeutic methods using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012871A Division KR102599945B1 (ko) 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법

Publications (2)

Publication Number Publication Date
KR20160136450A KR20160136450A (ko) 2016-11-29
KR102389552B1 true KR102389552B1 (ko) 2022-04-22

Family

ID=54321424

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167031180A Active KR102389552B1 (ko) 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법
KR1020227012871A Active KR102599945B1 (ko) 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227012871A Active KR102599945B1 (ko) 2014-04-17 2015-04-16 Mdm2 저해제 및 이 저해제를 사용하는 치료 방법

Country Status (12)

Country Link
US (1) US9745314B2 (Direct)
EP (1) EP3131544B1 (Direct)
JP (2) JP6694827B2 (Direct)
KR (2) KR102389552B1 (Direct)
CN (2) CN111718354A (Direct)
AU (1) AU2015247646B2 (Direct)
CA (1) CA2945527C (Direct)
ES (1) ES2712973T3 (Direct)
IL (2) IL248211B (Direct)
MX (2) MX373045B (Direct)
SG (2) SG10201913742TA (Direct)
WO (1) WO2015161032A1 (Direct)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US9745314B2 (en) * 2014-04-17 2017-08-29 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
US9962380B2 (en) * 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
KR20240158360A (ko) 2015-10-09 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
AU2017246452C1 (en) * 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN112041320B (zh) * 2017-12-29 2023-05-23 甘李药业股份有限公司 一种可用作肿瘤抑制剂的化合物及其制备方法与应用
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
EP3672595B1 (en) 2018-07-31 2021-07-21 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
EA202091963A1 (ru) 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГИЧЕСКИЙ ПРОТИВООПУХОЛЕВЫЙ ЭФФЕКТ ИНГИБИТОРА Bcl-2 В СОЧЕТАНИИ С РИТУКСИМАБОМ И/ИЛИ БЕНДАМУСТИНОМ ИЛИ ИНГИБИТОРА Bcl-2 В СОЧЕТАНИИ С CHOP
EA202091964A1 (ru) * 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
KR20210073490A (ko) * 2018-08-08 2021-06-18 어센테지 파마 (쑤저우) 컴퍼니 리미티드 면역요법과 mdm2 억제제의 병용
CN111214468B (zh) * 2018-11-23 2021-02-05 苏州亚盛药业有限公司 新型药物组合物及其用途
CA3095702A1 (en) * 2018-12-14 2020-06-18 Ascentage Pharma (Suzhou) Co., Ltd. A compound for treating osteoarthritis
TWI772753B (zh) * 2019-02-24 2022-08-01 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的治療方法和生物標記物
EP3814358B1 (en) * 2019-07-11 2025-09-03 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing 2-indolinospirone compounds and intermediates thereof
WO2021013028A1 (en) 2019-07-19 2021-01-28 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
US12194024B2 (en) * 2019-07-26 2025-01-14 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
TWI885019B (zh) 2019-11-27 2025-06-01 大陸商蘇州亞盛藥業有限公司 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
TWI777380B (zh) * 2020-01-23 2022-09-11 大陸商蘇州亞盛藥業有限公司 2-吲哚啉螺環酮類化合物之結晶形式
WO2021175192A1 (en) * 2020-03-02 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
PH12022552458A1 (en) * 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
US20230149356A1 (en) * 2020-04-14 2023-05-18 Ascentage Pharma (Suzhou) Co., Ltd. Novel medical use of mdm2 inhibitors
WO2021254277A1 (en) * 2020-06-15 2021-12-23 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeutic applications thereof
AU2021333983A1 (en) 2020-08-27 2023-01-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using MDM2 antagonists
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022170108A1 (en) * 2021-02-04 2022-08-11 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof in prevention of radiation injury
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023011488A1 (zh) 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023134707A1 (en) * 2022-01-11 2023-07-20 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating aml-mrc and mds
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264738A1 (en) * 2011-03-10 2012-10-18 Yuuichi Sugimoto Dispiropyrrolidine derivatives
US20120289494A1 (en) * 2011-05-11 2012-11-15 Sanofi Spiro-oxindole mdm2 antagonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
AU2006319248B2 (en) 2005-12-01 2012-09-27 F.Hoffman-La Roche Ag 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
ES2350504T3 (es) * 2006-03-13 2011-01-24 F. Hoffmann-La Roche Ag Derivados de espiroindolinona.
DE602007011902D1 (de) * 2006-03-13 2011-02-24 Hoffmann La Roche Spiroindolinon-derivate
JP5399904B2 (ja) * 2006-08-30 2014-01-29 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
US20080188506A1 (en) * 2007-02-07 2008-08-07 Qingjie Ding Spiroindolinone derivatives
RS52660B (sr) 2008-09-18 2013-06-28 F. Hoffmann-La Roche Ag Supstituisani pirolidin-2-karboksamidi
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
RU2553269C2 (ru) 2009-11-12 2015-06-10 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
EP2563360A4 (en) * 2010-04-09 2015-12-16 Univ Michigan BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN DISEASE TREATMENT
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
BR112016004593B1 (pt) * 2013-09-04 2022-12-06 Daiichi Sankyo Company, Limited Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto
US9745314B2 (en) * 2014-04-17 2017-08-29 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264738A1 (en) * 2011-03-10 2012-10-18 Yuuichi Sugimoto Dispiropyrrolidine derivatives
US20120289494A1 (en) * 2011-05-11 2012-11-15 Sanofi Spiro-oxindole mdm2 antagonists

Also Published As

Publication number Publication date
EP3131544A1 (en) 2017-02-22
JP6909323B2 (ja) 2021-07-28
IL248211B (en) 2019-10-31
CA2945527C (en) 2022-05-17
IL269462B (en) 2021-05-31
NZ724963A (en) 2021-10-29
CA2945527A1 (en) 2015-10-22
SG11201608667SA (en) 2016-11-29
MX2020003939A (es) 2020-08-13
CN111718354A (zh) 2020-09-29
IL248211A0 (en) 2016-11-30
IL269462A (en) 2019-11-28
CN106794171B (zh) 2020-03-24
JP2017511360A (ja) 2017-04-20
AU2015247646A1 (en) 2016-10-27
KR102599945B1 (ko) 2023-11-09
ES2712973T3 (es) 2019-05-17
US9745314B2 (en) 2017-08-29
EP3131544B1 (en) 2018-12-12
EP3131544A4 (en) 2017-08-30
AU2015247646B2 (en) 2019-06-06
JP6694827B2 (ja) 2020-05-20
MX373045B (es) 2020-05-26
CN106794171A (zh) 2017-05-31
KR20220054697A (ko) 2022-05-03
WO2015161032A1 (en) 2015-10-22
KR20160136450A (ko) 2016-11-29
US20150299211A1 (en) 2015-10-22
MX2016013457A (es) 2017-05-04
JP2020100662A (ja) 2020-07-02
SG10201913742TA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
KR102389552B1 (ko) Mdm2 저해제 및 이 저해제를 사용하는 치료 방법
JP6251301B2 (ja) スピロ−オキシインドールｍｄｍ２アンタゴニスト
RU2553269C2 (ru) Спирооксиндольные антагонисты mdm2
JP5399904B2 (ja) Ｍｄｍ２の小分子阻害剤およびその使用
WO2015153959A2 (en) Small molecule inhibitors of mcl-1 and uses thereof
KR20140027913A (ko) 스피로­옥신돌 ｍｄｍ２ 길항제
EP2831067A1 (en) Small molecule inhibitors of mcl-1 and uses thereof
JP2008533039A (ja) 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用
JP2019537604A (ja) Ｅｇｆｒ／ｐｉ３ｋの小分子二重阻害剤及びその使用
US20230133958A1 (en) Compounds useful in modulating egfr and pi3k
WO2020123670A1 (en) Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
NZ724963B2 (en) Mdm2 inhibitors and therapeutic methods using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210611

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220118

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220418

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220419

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220420

End annual number: 3

Start annual number: 1

PG1601 Publication of registration